FDA approves Biogen's $56,000 drug for Alzheimer's
The Food and Drug Administration of the US approved on Monday Biogen Inc's Aducanumab to treat Alzheimer's disease amidst the controversy of its efficacy.
Source: industryleadersmagazine.com
Stay updated with breaking news from Reshma Ramachandra. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Food and Drug Administration of the US approved on Monday Biogen Inc's Aducanumab to treat Alzheimer's disease amidst the controversy of its efficacy.